Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011221 - SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE MESYLATE SALT

Publication Number WO/2022/011221
Publication Date 13.01.2022
International Application No. PCT/US2021/041028
International Filing Date 09.07.2021
IPC
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 405/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
A61K 31/4725 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
472Non-condensed isoquinolines, e.g. papaverine
4725containing further heterocyclic rings
Applicants
  • TEVA CZECH INDUSTRIES S.R.O [CZ]/[CZ]
  • TEVA PHARMACEUTICALS USA, INC. [US]/[US] (BB)
Inventors
  • KOLESA, Pavel
  • VAVREČKA, Miroslav
  • GABRIEL, Roman
  • VALÍK, Martin
Agents
  • BREW, Michael R.
  • DELUCA, Peter
  • MEAGHER, Edward C.
Priority Data
63/050,17810.07.2020US
63/057,95929.07.2020US
63/158,93410.03.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE MESYLATE SALT
(FR) FORMES À L'ÉTAT SOLIDE DE SEL DE MÉSYLATE N-[2-(2-{4-[2-(6,7-DIMÉTHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ÉTHYL]PHÉNYL}-2H-TÉTRAZOL-5-YL)-4,5-DIMÉTHOXYPHÉNYL]-4-OXO-4H-CHROMÈNE-2-CARBOXAMIDE
Abstract
(EN) The present disclosure relates to solid state forms of Encequidar and Encequidar mesylate, processes for their preparation, and pharmaceutical compositions thereof.
(FR) La présente invention concerne des formes à l'état solide d'encequidar et de mésylate d'encequidar, des procédés pour leur préparation et des compositions pharmaceutiques correspondantes.
Latest bibliographic data on file with the International Bureau